Compounders Research Compare

MoonLake Immunotherapeutics(MLTX)

Biotechnology · Zug, ZG

$11.16-0.22 (-1.91%)

Delayed quote: Oct 6, 2026, 12:55 PM EDT

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

Zug, ZG

130 employees

www.moonlaketx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jorge Santos da Silva

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:31.688Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:57:31.688Z.

Quote observation: 2026-10-06T16:55:14.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 938,921,329
Total debt · period ending 2026-06-30: 101,532,000
Cash · period ending 2026-06-30: 477,905,000
TTM operating EBITDA · period ending 2026-06-30: -265,099,000

FMP input reference: 69a1d57d3f318828ebe19021960b74268097702d5d6050a421f3255bba496414

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

MLTX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

MLTX Competitors' EV/EBITDA Ratio

MoonLake Immunotherapeutics

Current

Market Cap

$938.92M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CeriBell, Inc.

Market Cap

$931.25M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kura Oncology, Inc.

Market Cap

$949.00M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Seaport Therapeutics, Inc. Common Stock

Market Cap

$950.17M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Savara Inc.

Market Cap

$952.91M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Odyssey Therapeutics, Inc.

Market Cap

$919.80M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HealthStream, Inc.

Market Cap

$915.31M

EV/EBITDA Ratio

12.55x

TTM Avg

10.56x

3Y Avg

12.81x

5Y Avg

13.69x

Aktis Oncology, Inc.

Market Cap

$966.65M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bioventus Inc.

Market Cap

$898.03M

EV/EBITDA Ratio

10.57x

TTM Avg

9.34x

3Y Avg

18.56x

5Y Avg

25.76x

LB Pharmaceuticals Inc Common Stock

Market Cap

$979.98M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
MoonLake Immunotherapeutics (MLTX)	$938.92M	N/A	N/A	N/A	N/A
CeriBell, Inc. (CBLL)vs ›	$931.25M	N/A	N/A	N/A	N/A
Kura Oncology, Inc. (KURA)vs ›	$949.00M	N/A	N/A	N/A	N/A
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$950.17M	N/A	N/A	N/A	N/A
Savara Inc. (SVRA)vs ›	$952.91M	N/A	N/A	N/A	N/A
Odyssey Therapeutics, Inc. (ODTX)vs ›	$919.80M	N/A	N/A	N/A	N/A
HealthStream, Inc. (HSTM)vs ›	$915.31M	12.55x	10.56x	12.81x	13.69x
Aktis Oncology, Inc. (AKTS)vs ›	$966.65M	N/A	N/A	N/A	N/A
Bioventus Inc. (BVS)vs ›	$898.03M	10.57x	9.34x	18.56x	25.76x
LB Pharmaceuticals Inc Common Stock (LBRX)vs ›	$979.98M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics